Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTH NASDAQ:OBLN OTCMKTS:RDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.16$0.00$0.16▼$1.57$763K4.024,068 shsN/AOBLNObalon Therapeutics$2.13+0.9%$4.22$0.66▼$10.77$21.35M-1.237.68 million shs12,576 shsRDGLAdvanced Medical Isotope$0.07+8.7%$0.07$0.04▼$0.15$30.07M-0.76780,491 shs1.50 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%+13,300.00%+13,300.00%+13,300.00%OBLNObalon Therapeutics0.00%0.00%0.00%+2.40%-25.78%RDGLAdvanced Medical Isotope+8.70%+8.35%+2.48%-26.53%-50.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.16$0.00$0.16▼$1.57$763K4.024,068 shsN/AOBLNObalon Therapeutics$2.13+0.9%$4.22$0.66▼$10.77$21.35M-1.237.68 million shs12,576 shsRDGLAdvanced Medical Isotope$0.07+8.7%$0.07$0.04▼$0.15$30.07M-0.76780,491 shs1.50 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%+13,300.00%+13,300.00%+13,300.00%OBLNObalon Therapeutics0.00%0.00%0.00%+2.40%-25.78%RDGLAdvanced Medical Isotope+8.70%+8.35%+2.48%-26.53%-50.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AOBLNObalon Therapeutics 0.00N/AN/AN/ARDGLAdvanced Medical Isotope 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K9.53N/AN/A($2.43) per share-0.07OBLNObalon Therapeutics$1.59M13.43N/AN/A$0.60 per share3.55RDGLAdvanced Medical Isotope$70K466.94N/AN/A($0.02) per share-3.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98M-$2.34N/AN/AN/A-8,257.70%N/A-730.22%N/AOBLNObalon Therapeutics-$12.33MN/AN/AN/AN/A-776.76%-161.38%-83.58%N/ARDGLAdvanced Medical Isotope-$3.07M-$0.01N/AN/AN/A-4,380.77%N/A-138.20%N/ALatest RDGL, ARTH, and OBLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/30/2026Q4 2025RDGLAdvanced Medical IsotopeN/A-$0.01N/A-$0.01N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/ARDGLAdvanced Medical IsotopeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01OBLNObalon TherapeuticsN/A1.861.86RDGLAdvanced Medical IsotopeN/A15.1314.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%OBLNObalon Therapeutics18.64%RDGLAdvanced Medical IsotopeN/AInsider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%OBLNObalon Therapeutics8.10%RDGLAdvanced Medical Isotope18.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionableRDGLAdvanced Medical Isotope1493.74 million402.40 millionNot OptionableRDGL, ARTH, and OBLN HeadlinesRecent News About These CompaniesVivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® ManufacturingJune 11, 2026 | globenewswire.comVivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™June 5, 2026 | globenewswire.comVivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production SitesFebruary 17, 2026 | globenewswire.comVivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™February 10, 2026 | globenewswire.comVivos Inc Updates Human Therapy Progress in IndiaFebruary 3, 2026 | globenewswire.comVivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark ApprovalsJanuary 28, 2026 | globenewswire.comVivos Inc Summarizes Progress in its Animal Therapy DivisionDecember 22, 2025 | globenewswire.comVivos Inc Summarzes Preogress in its Animal Therapy DivisionDecember 22, 2025 | globenewswire.comVivos Inc. Issues Shareholder Update LetterNovember 6, 2025 | globenewswire.comVivos Inc. Strengthens Strategic Collaboration with Exubrion TherapeuticsOctober 29, 2025 | globenewswire.comVivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D.October 27, 2025 | globenewswire.comVivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in IndiaSeptember 29, 2025 | globenewswire.comVivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in IndiaSeptember 29, 2025 | globenewswire.comVivos Inc. Demonstrates Precision in Precision Radionuclide TherapySeptember 8, 2025 | globenewswire.comVivos Inc Files Critical Patent For Hydrogel Electron Beam SterilizationSeptember 3, 2025 | globenewswire.comInvestigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDAAugust 14, 2025 | globenewswire.comVivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo ClinicJuly 14, 2025 | globenewswire.comVivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™May 15, 2025 | globenewswire.comVivos Inc.May 8, 2025 | marketwatch.comVivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025April 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird SatellitesBy Jessica Mitacek | June 16, 2026Planet Labs: Coming Back Down to EarthBy Chris Markoch | June 8, 2026Palomar’s High-Risk Insurance Strategy Is Paying Off BigBy Peter Frank | May 29, 2026USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsBy Leo Miller | May 20, 2026RDGL, ARTH, and OBLN Company DescriptionsArch Therapeutics OTCMKTS:ARTH$0.16 0.00 (0.00%) As of 06/16/2026Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Obalon Therapeutics NASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.Advanced Medical Isotope OTCMKTS:RDGL$0.07 +0.01 (+8.70%) As of 06/17/2026 03:59 PM EasternVivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
